Beleaguered Merck looks to future A week after saying it was withdrawing its \$2.5 billion arthritis drug Vioxx from the market and losing a quarter of its stock market value as a result, Merck  amp; Co. will try to dodge the storm clouds and turn its attention tomorrow to a brighter subject with the official opening of its Boston research lab.